CTNM
Contineum Therapeutics, Inc. · Healthcare · Market cap $312.9M
Insiders sold $1.1M net in the last 90 days ·3 sellers, 0 buyers· 9 of 9 sales under Rule 10b5-1 plans· latest Form 4 filed Sep 8, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.9M
reported sales (SEC code S)
Unique Insiders
3
in the rolling window
Latest filing
Sep 8, 2026
Stengone Carmine N.
Contineum Therapeutics, Inc. (CTNM) has 22 SEC Form 4 filings (51 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: Sep 8, 2026.
Inside the rolling window, 3 insiders at Contineum Therapeutics, Inc. reported no open-market purchases and 26 open-market sales totaling $1.9M. The most active filer is Chief Scientific Officer Lorrain Daniel S. with 15 filings. Insiders have net sold $1.2M over the trailing 6 months. The most recent open-market filing is a sale of 2,500 shares by CEO and President Stengone Carmine N., dated Sep 8, 2026, worth $41K.
- Industry:Biotechnology
- CEO:Carmine N. Stengone
- Employees:51
- HQ:San Diego, CA, US
- IPO:2024-04-04
| Source | |||||||
|---|---|---|---|---|---|---|---|
| CEO and President | Sale | 2,500 | $41K | Sep 8 | -47.6% | SEC ↗ | |
| CEO and President | Sale | 2,500 | $40K | Aug 3 | -47.6% | SEC ↗ | |
| Chief Scientific Officer | Sale | 1,015 | $16K | Jul 10 | -45.0% | SEC ↗ | |
| Chief Scientific Officer | Sale | 25 | $400 | Jul 10 | -45.0% | SEC ↗ | |
| CEO and President | Sale | 2,500 | $40K | Jul 8 | -46.6% | SEC ↗ | |
| Chief Scientific Officer | Sale | 28,826 | $462K | Jul 2 | -44.7% | SEC ↗ | |
| Chief Scientific Officer | Sale | 8,353 | $132K | Jul 2 | -44.7% | SEC ↗ | |
Watkins TimFirst in 4 months | CMO & Head of Development | Sale | 10,833 | $174K | Jul 1 | -45.2% | SEC ↗ |
Stengone Carmine N.First in 4 months | CEO and President | Sale | 10,000 | $160K | Jul 1 | -45.2% | SEC ↗ |
| Chief Scientific Officer | Sale | 4,170 | $55K | Jun 1 | — | SEC ↗ | |
| Chief Scientific Officer | Sale | 4,170 | $55K | May 1 | — | SEC ↗ | |
| Chief Scientific Officer | Sale | 4,170 | $56K | Apr 6 | — | SEC ↗ | |
| CMO & Head of Development | Sale | 3,611 | $54K | Mar 2 | — | SEC ↗ | |
| Chief Scientific Officer | Sale | 4,170 | $63K | Mar 2 | — | SEC ↗ | |
| Chief Scientific Officer | Sale | 4,300 | $69K | Feb 26 | — | SEC ↗ | |
| Chief Scientific Officer | Sale | 3,824 | $61K | Feb 26 | — | SEC ↗ | |
| CEO and President | Sale | 4,400 | $70K | Feb 26 | — | SEC ↗ | |
| CEO and President | Sale | 2,700 | $43K | Feb 26 | — | SEC ↗ | |
| Chief Scientific Officer | Sale | 100 | $2K | Feb 20 | — | SEC ↗ | |
| Chief Scientific Officer | Sale | 400 | $6K | Feb 13 | — | SEC ↗ | |
Stengone Carmine N.First filing | CEO and President | Sale | 400 | $6K | Feb 13 | — | SEC ↗ |
| Chief Scientific Officer | Sale | 4,170 | $62K | Feb 5 | — | SEC ↗ | |
| CMO & Head of Development | Sale | 3,611 | $51K | Jan 30 | — | SEC ↗ | |
| Chief Scientific Officer | Sale | 4,170 | $44K | Jan 6 | — | SEC ↗ | |
Watkins TimFirst filing | CMO & Head of Development | Sale | 3,611 | $44K | Dec 30 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does CTNM have?
Contineum Therapeutics, Inc. (CTNM) has 22 SEC Form 4 filings (51 transaction rows) in the rolling 365-day window, disclosed by 3 distinct insiders. Most recent filing: Sep 8, 2026.
When was the most recent SEC Form 4 filing for CTNM?
The most recent Form 4 filing for CTNM on Tracefour is dated Sep 8, 2026.
Who is the most active insider at CTNM?
The most active SEC Form 4 filer at CTNM in the rolling window is Chief Scientific Officer Lorrain Daniel S., with 15 filings.
What is the net insider flow at CTNM over the last 6 months?
Over the trailing 180 days, insiders at CTNM have net sold $1.2M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at CTNM in the current window?
Inside the rolling window, insiders at CTNM bought $0 and sold $1.9M based on SEC Form 4 filings.
Can I get alerts for CTNM insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Contineum Therapeutics, Inc. (CTNM). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Contineum Therapeutics, Inc. is in the Healthcare sector.